Trial Profile
Study to evaluate the pharmacokinetics of Daclizumab high yield process, after multiple subcutaneous administration, in patients with relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2015
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- 15 Jun 2015 New trial record
- 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.